Traders should monitor for future clinical development updates or partnership announcements related to the Nanoprimer platform, as these preclinical results could increase interest in Nanobiotix as a potential collaborator in the LNP and gene therapy space.
Price Chart
Executive Summary
Nanobiotix announced preclinical data showing that its Nanoprimer technology improves systemic bioavailability and reduces hepatic toxicity and inflammatory response when used prior to LNP-delivered DNA immunotherapy. The data were presented at the 2026 AACR Annual Meeting.
Key Facts
- Preclinical study in mice demonstrated that Nanoprimer pre-treatment enhances systemic bioavailability of LNP-DNA immunotherapies
- Nanoprimer reduced liver uptake and toxicity of LNP-DNA, improving hepatic tolerability
- The technology attenuated activation of the cGAS-STING inflammatory pathway
- Data support Nanoprimer's potential to optimize advanced LNP-based therapies designed for extrahepatic delivery
- Results were generated in collaboration with Earli and presented at AACR 2026
Financial Impact
No direct financial impact reported; preclinical data may enhance platform valuation and partnership potential
Risk Factors
- Preclinical results may not translate to human clinical efficacy
- Forward-looking statements are subject to risks including failure to realize projected timelines or therapeutic benefits
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-002539 |
| Document: f6k_041926.htm | 0001171843-26-002539 |
| Document: 0001171843-26-002539-index-headers.html | 0001171843-26-002539 |
| Document: 0001171843-26-002539-index.html | 0001171843-26-002539 |
| Document: 0001171843-26-002539.txt | 0001171843-26-002539 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+20 | — | — |
Oct 20, 2026 6d ago | 6-K | $25.83 | awaiting T+20 | — | $29.36 (+13.67%) |
Oct 1, 2026 25d ago | 6-K | $25.75 | awaiting T+20 | — | $29.36 (+14.02%) |
Oct 1, 2026 25d ago | Press Release | $25.75 | awaiting T+20 | — | $29.36 (+14.02%) |
Sep 24, 2026 4w ago | 6-K | $33.31 $29.36 | ▲ +11.86% | ▲ +10.38% | $29.36 (+11.86%) |
Sep 24, 2026 4w ago | 6-K | $33.31 $29.36 | ▼ −11.86% | ▼ −10.38% | $29.36 (−11.86%) |
Sep 24, 2026 4w ago | Press Release | $33.31 $29.36 | ▼ −11.86% | ▼ −10.38% | $29.36 (−11.86%) |
Sep 22, 2026 4w ago | Press Release | $35.24 $25.83 | ▼ −26.70% | ▼ −27.39% | $29.36 (−16.69%) |
Sep 14, 2026 6w ago | 6-K | $35.73 $23.40 | ▼ −34.51% | ▼ −36.77% | $29.36 (−17.83%) |
Jul 31, 2026 12w ago | 6-K | $38.89 $40.64 | ▲ +4.50% | ▲ +3.26% | $29.36 (−24.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers